Renee joined the team in 2016 as Carlson’s life sciences expert, with 10+ years of experience in the medical device, biotechnology, and diagnostics industries. Her unique skill set, which spans financial planning and analysis, research and development, marketing, project management, and investor relations, provides her with a broad, yet in-depth, understanding of the industry.
In a former role, she was an Adaptive Insights power user and employed best practices in budgeting, forecasting, and planning in developing client models. Prior experience includes raising capital, leading efforts in gross margin improvements, evaluating acquisition targets, managing product-related programs that resulted in FDA approvals and led to successful commercialization, and developing/deploying financial planning analysis programs at two organizations.
She has implemented Adaptive Insights for pre-commercial and commercial companies within the life sciences, in addition to clinical research organizations and non-profits within the space.
Renee has a Bachelor’s and a Master’s degree in Biomedical Engineering from Case Western Reserve University and a Master’s in Business Administration, with concentrations in Healthcare and Finance, from Boston University. She is Adaptive Insights certified.
- Commercial operations analysis and reporting
- Financial planning
- Gross margin analysis
- Management & board reporting
- Financial modeling
- Project management
- Scenario analysis
- Variance analysis
Before joining Carlson, Renee’s experience included:
- Senior Manager, Financial Planning & Analysis at Good Start Genetics, Inc.
- Manager, Business & Financial Analysis at Organogenesis, Inc.
Relevant Projects: Acidophil LLC, Akebia Therapeutics, Alnylam Pharmaceuticals, American Telemedicine Association, Avrobio Beam Therapeutics, Genevant, Heron Therapeutics, Idera Pharmaceuticals, Juniper Pharmaceuticals, Kiniksa Pharmaceuticals, Magenta Therapeutics, Metabolon Inc., National Organization for Rare Diseases, Neurophage, Organogenesis Inc., Peachtree Bioresearch Solutions, Rubius Therapeutics, Scholar Rock, Seattle Cancer Care Alliance, Tetraphase Pharmaceuticals, Vertice Pharmaceuticals
“Renee has been a trusted partner throughout our Adaptive Insights implementation and after going live. Her domain knowledge in the life sciences allowed her to quickly understand our current and evolving business requirements. Her specialized project experience in our market enabled her to impart finance and systems best practices, which contributed to a highly successful project. She continues to add value to our FP&A team, most recently with an expanded cash flow delivered in a short time-frame.”
Carri Dyment, Director of Accounting and HR, SCCA Proton Therapy Center